Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacometrics of zoledronic acid in BRONJ
NCT02069340Withdrawn
- Sponsor
- University of Southern California
- Start
- Jun 2016
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Randomised, open-label trial of zoledronic acid in malignant neoplasm, sponsored by University of Southern California. Primary endpoint: Plasma concentrations of zoledronic acid at 1 month. Planned start Jun 2016; status: withdrawn.
02
Drugs
zoledronic acid
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT02069340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069340.